- About TapImmune
- News & Media
- Contact Us
SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer New York, NY / ACCESSWIRE / September 18, 2014 /...
All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients...